Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis
Shintaro Akiyama, Shadi Hamdeh, Dejan Micić, et al.
Annals of the Rheumatic Diseases (2020) Vol. 80, Iss. 3, pp. 384-391
Open Access | Times Cited: 366

Showing 51-75 of 366 citing articles:

COVID-19 Immunobiology: Lessons Learned, New Questions Arise
Aimilios Kaklamanos, Konstantinos Belogiannis, Panagiotis Skendros, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 33
Coronavirus disease 2019 (COVID-19) and autoimmunity
Е. Л. Насонов
Rheumatology Science and Practice (2021) Vol. 59, Iss. 1, pp. 5-30
Open Access | Times Cited: 32
COVID-19 and rheumatoid arthritis
Kristin M. D’Silva, Zachary S. Wallace
Current Opinion in Rheumatology (2021) Vol. 33, Iss. 3, pp. 255-261
Open Access | Times Cited: 32
COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis
René Cordtz, Salome Kristensen, Rasmus Westermann, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 1, pp. 77-88
Open Access | Times Cited: 26
Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis
Feier Wang, Yubo Ma, Shanshan Xu, et al.
Clinical Rheumatology (2022) Vol. 41, Iss. 7, pp. 2213-2223
Open Access | Times Cited: 25
COVID-19 disease and autoimmune disorders: A mutual pathway
Mohammed Al‐Beltagi, Nermin Kamal Saeed, Adel Salah Bediwy
World Journal of Methodology (2022) Vol. 12, Iss. 4, pp. 200-223
Open Access | Times Cited: 24
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Zhigang Liu, Kaixing Le, Xin Zhou, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 145-156
Open Access | Times Cited: 24
Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities
Anna Campanati, Federico Diotallevi, Emanuela Martina, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2422-2422
Open Access | Times Cited: 23
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
Stefan Schreiber, Shomron Ben‐Horin, Rieke Alten, et al.
Advances in Therapy (2022) Vol. 39, Iss. 6, pp. 2342-2364
Open Access | Times Cited: 22
Bioinformatics analysis of potential common pathogenic mechanisms for COVID-19 infection and primary Sjogren’s syndrome
Hong Luo, Xia Zhou
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 22
Risks of mortality and severe coronavirus disease 19 (COVID-19) outcomes in patients with or without systemic lupus erythematosus
Sebastian Bruera, Xiudong Lei, Hui Zhao, et al.
Lupus Science & Medicine (2023) Vol. 10, Iss. 1, pp. e000750-e000750
Open Access | Times Cited: 13
Prevalence of poor sleep quality in COVID-19 patients: a systematic review and meta-analysis
Zhen Gui, Yueying Wang, Jiaxin Li, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 4
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes
Rebecca Grainger, Pedro Machado, Philip C. Robinson
Best Practice & Research Clinical Rheumatology (2020) Vol. 35, Iss. 1, pp. 101657-101657
Open Access | Times Cited: 36
SARS-CoV-2 infection in patients with systemic autoimmune diseases
Pilar Brito‐Zerón, Antoni Sisó‐Almirall, Alejandra Flores-Chávez, et al.
Clinical and Experimental Rheumatology (2021) Vol. 39, Iss. 3, pp. 676-687
Open Access | Times Cited: 31
SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage
Mohsen Karami Fath, Abolfazl Jahangiri, Mahmoud Ganji, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 31
COVID-19 prevalence, symptoms, and sociodemographic disparities in infection among insured pregnant women in Northern California
Jennifer Ames, Assiamira Ferrara, Lyndsay A. Avalos, et al.
PLoS ONE (2021) Vol. 16, Iss. 9, pp. e0256891-e0256891
Open Access | Times Cited: 31
COVID-19 infection among autoimmune rheumatic disease patients: Data from an observational study and literature review
Athanasios‐Dimitrios Bakasis, Clio P. Mavragani, Kyriaki Boki, et al.
Journal of Autoimmunity (2021) Vol. 123, pp. 102687-102687
Open Access | Times Cited: 30
Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID‐19 pandemic
Lai‐Shan Tam, Yoshiya Tanaka, Rohini Handa, et al.
International Journal of Rheumatic Diseases (2021) Vol. 24, Iss. 6, pp. 733-745
Open Access | Times Cited: 29
A novel multi-omics-based highly accurate prediction of symptoms, comorbid conditions, and possible long-term complications of COVID-19
Debmalya Barh, Sandeep Tiwari, Bruno Andrade, et al.
Molecular Omics (2021) Vol. 17, Iss. 2, pp. 317-337
Open Access | Times Cited: 28
Poor Prognosis of COVID‐19 Acute Respiratory Distress Syndrome in Lupus Erythematosus: Nationwide Cross‐Sectional Population Study Of 252 119 Patients
Isabela Maria Bertoglio, Juliana Miranda de Lucena Valim, Danielle Daffre, et al.
ACR Open Rheumatology (2021) Vol. 3, Iss. 11, pp. 804-811
Open Access | Times Cited: 28
Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review
Beatriz Garcillán, Miguel Salavert, José R. Regueiro, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 297-297
Open Access | Times Cited: 20
Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study
Sandra Maximiano de Oliveira, Lucas Victória de Oliveira Martins, Ana Paula Lupino-Assad, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 55, pp. 151987-151987
Open Access | Times Cited: 20
SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases
Regina Larionova, K. Byvaltsev, О. А. Кравцова, et al.
Journal of Translational Autoimmunity (2022) Vol. 5, pp. 100154-100154
Open Access | Times Cited: 20
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
K. H. Bjørlykke, Hilde S Ørbo, Anne Therese Tveter, et al.
The Lancet Rheumatology (2022) Vol. 5, Iss. 1, pp. e36-e46
Open Access | Times Cited: 20
A Review Pertaining to SARS-CoV-2 and Autoimmune Diseases: What Is the Connection?
Nina Kocivnik, Tomaž Velnar
Life (2022) Vol. 12, Iss. 11, pp. 1918-1918
Open Access | Times Cited: 18

Scroll to top